Key result
High baseline Lp(a) blunts plaque lipid core reduction with alirocumab after acute MI.
Why the study?
Does baseline Lp(a) attenuate the regression of coronary atherosclerosis in patients with acute myocardial infarction treated with alirocumab and high-intensity statins?
RCT (n=300)
Does baseline Lp(a) attenuate the regression of coronary atherosclerosis in patients with acute myocardial infarction treated with alirocumab and high-intensity statins?
Answers are grounded in this paper and cite their sources.
Elevated baseline Lp(a) is associated with attenuated plaque lipid regression in AMI patients treated with alirocumab and high-intensity statins, potentially explaining residual cardiovascular risk.
BACKGROUND: Elevated Lp(a) (lipoprotein[a]) is a risk marker for atherosclerotic disease, but the underlying mechanisms remain elusive. We examined the association of Lp(a) with changes in coronary atherosclerosis following intensive lipid-lowering therapy. METHODS: In the PACMAN-AMI trial (Effects of the PCSK9 Antibody Alirocumab on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction), 300 patients with acute myocardial infarction were randomized to receive biweekly alirocumab 150 mg or placebo in addition to high-intensity statins. Patients underwent serial 2-vessel intravascular ultrasound, optical coherence tomography, and near-infrared spectroscopy in the non–infarct-related arteries at baseline and after 52 weeks. The main end points were percent atheroma volume by intravascular ultrasound, minimum fibrous cap thickness by optical coherence tomography, and maximum lipid core burden index within 4 mm (maxLCBI 4mm ) by near-infrared spectroscopy. RESULTS: A total of 265 patients had serial intravascular ultrasound data (mean age, 58±9 years; 16% women). Alirocumab resulted in greater reductions in percent atheroma volume and maxLCBI 4mm , as well as a greater increase in minimum fibrous cap thickness, compared with placebo. In the alirocumab group, the reduction in maxLCBI 4mm was smaller in patients with higher baseline Lp(a), defined by the highest quartile (Q4, ≥98 nmol/L; n=30), than in those with lower baseline Lp(a) (Q1–Q3, <98 nmol/L; n=99; −40.2 [−91.1 to 10.7] versus −91.4 [−113.9 to −68.9], respectively; P =0.01 after adjustment for clinically relevant baseline variables), and was comparable to the maxLBI 4mm reduction in the placebo group (−37.60 [−57.40 to −17.80]; n=134). These findings were consistent when higher baseline Lp(a) was defined by cut-off values of ≥75 versus <75 nmol/L (n=35 versus 94, respectively, in the alirocumab group) and ≥125 versus <125 nmol/L (n=23 versus 106, respectively). Changes in percent atheroma volume and minimum fibrous cap thickness did not differ in relation to baseline Lp(a). CONCLUSIONS: In patients with acute myocardial infarction, elevated Lp(a) at baseline is associated with attenuation of plaque lipid regression despite intensive treatment with alirocumab plus high-intensity statin. This finding may explain the residual cardiovascular risk associated with high Lp(a) despite optimal control of lipid levels. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03067844.
No takes yet. Share an insight, caveat, or question.
Koskinas et al. (2024) conducted an RCT in acute myocardial infarction (n=300). Alirocumab vs. Placebo was evaluated on percent atheroma volume, minimum fibrous cap thickness, and maximum lipid core burden index within 4 mm (maxLCBI 4mm) (p=0.01). In patients with acute myocardial infarction treated with alirocumab, elevated baseline Lp(a) was associated with attenuated reduction in maxLCBI 4mm compared to lower Lp(a).
Synapse has enriched 10 related papers. Consider them for comparative context: